샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731075

세계의 강심제 시장

Cardiotonic Agents
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 568 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

강심제 세계 시장은 2030년까지 30억 달러에 도달

2024년에 10억 달러로 추정되는 강심제 세계 시장은 2024-2030년 CAGR 19.4%로 성장하여 2030년에는 30억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Digitalis Glycosides는 CAGR 21.6%를 나타내고, 분석 기간 종료시에는 12억 달러에 이를 것으로 예측됩니다. 포스포디에스테라아제 억제제 부문의 성장률은 분석 기간중 CAGR 20.5%로 추정됩니다.

미국 시장은 2억 8,470만 달러로 추정, 중국은 CAGR 26.5%를 보일 것으로 예측

미국의 강심제 시장은 2024년에 2억 8,470만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 7억 2,080만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 26.5%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 각각 분석 기간 중에 15.3%와 17.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 유럽에서는 독일이 CAGR 약 16.3%를 보일 전망입니다.

세계의 강심제 시장 - 주요 동향과 성장 촉진요인 정리

강심제가 다양한 의료 현장에서 급성 심부전 및 만성 심부전 관리에 필수적인 이유는 무엇일까요?

심근 수축력을 강화하는 데 주로 사용되는 강심제는 심부전, 심인성 쇼크, 특정 부정맥의 약리학적 관리의 핵심입니다. 디기탈리스 배당체(예: 디곡신), 포스포디에스터라아제 억제제(예: 미를리논), 아드레날린 작용제(예: 도부타민)를 포함한 이러한 약물은 박출률 감소 또는 심박출량 감소 시 중요한 혈역학적인 지원을 제공합니다. 새로운 심부전 치료제의 등장에도 불구하고, 강심제는 빠른 약효 발현, 급성 탈락 시 유용성, 집중 치료 및 장기 심부전 치료 알고리즘에서 확립된 역할로 인해 임상적 중요성을 유지하고 있습니다.

중환자실이나 응급실과 같은 급성기에는 생명을 위협할 정도로 심기능이 저하된 환자의 안정화에 강심제가 필수적입니다. 만성기 치료에서는 심방세동의 심박수 조절과 박출률 저하형 심부전(HFrEF) 입원 환자를 줄이기 위해 디곡신과 같은 선택적 약물이 사용됩니다.

새로운 약물 전달 모델과 위험 관리 전략은 강심제 사용을 어떻게 촉진하고 있는가?

특히 디곡신과 같은 오래된 약물의 경우, 독성 및 좁은 치료 범위에 대한 우려로 인해 역사적으로 광범위한 사용이 제한되어 왔으나, 투여 프로토콜, 치료 약물 모니터링(TDM), 맞춤 치료 요법의 발전으로 인해 안전성과 임상 결과가 개선되고 있습니다. 정맥주사 제제는 여전히 급성기 치료의 중심이며, 경구용 제제는 만성기 유지요법에 사용되고 있습니다. 강화된 약물감시, 디지털 모니터링 도구, 환자별 위험 평가 모델은 임상의가 용량을 최적화하고, 부작용을 최소화하며, 보다 광범위한 환자군으로 안전한 사용을 확대할 수 있도록 돕고 있습니다.

또한, 임상시험 및 관찰 연구를 통해 강심제와 RAAS 억제제, SGLT2 억제제, 베타차단제와의 병용 전략에 대한 관심이 다시금 높아지고 있습니다. 이와 함께 심근 효율을 개선하고 부정맥 위험 프로파일을 낮춘 차세대 강심제 연구도 진행 중이며, 현대 심부전 치료에서 수축력 강화제의 역할을 재정의하는 것을 목표로 하고 있습니다.

강심제에 대한 수요가 증가하고 있는 곳은 어디이며, 어떤 임상 부문이 강심제 사용을 주도하고 있는가?

북미와 유럽은 심부전 유병률이 높고, 중환자실 인프라가 잘 갖추어져 있으며, 급성기 치료 프로토콜이 널리 사용되고 있기 때문에 여전히 주요 시장입니다. 특히 미국에서는 병원에서 정맥 내 강심제 사용이 계속 확대되고 있습니다. 아시아태평양, 특히 중국, 인도, 동남아시아에서 수요가 크게 증가하고 있으며, 심혈관 질환 증가, 인구 고령화, 중환자 치료 접근성 확대가 이용 확대를 촉진하고 있습니다.

강심제는 급성 심부전, 수술 후 심장 보조, 진행성 심부전 등 다른 약물 요법이 불충분한 경우에 널리 사용됩니다. 사용 빈도가 높은 분야는 순환기 병동, 중환자실, 응급실, 응급실, 심장 수술 회복 프로그램 등입니다. 또한, 외래 심부전 클리닉과 노인 의료 센터에서는 특정 환자군의 만성 유지 요법에 저용량 요법을 사용하고 있습니다.

강심제 시장의 세계 성장 원동력은?

세계 강심제 시장은 심부전 발병률 증가, 즉각적인 심혈관계 치료제에 대한 수요 증가, 급성 감압증에서 강심제 및 심박수 조절제에 대한 임상적 의존도가 지속됨에 따라 성장하고 있습니다. 심부전 치료가 보다 프로토콜 중심적이고 환자 중심적으로 변화하는 가운데, 강심제는 혈역학을 안정시키고 환자를 장기적인 치료, 중재 및 이식에 연결시키는 데 필수적인 도구로 자리매김하고 있습니다.

제형 개선, 용량 유연성, 안전성 모니터링 등 의약품의 혁신은 임상적 신뢰를 유지하는 데 도움이 되고 있으며, 전 세계적으로 심장 치료에 대한 접근성 확대는 중저소득 국가에 새로운 시장을 개척하고 있습니다. 심부전 환자 증가와 자원의 제약으로 인해 의료 시스템이 어려움을 겪고 있는 가운데, 미래를 결정짓는 중요한 문제가 있습니다. 강심제는 안전성 향상, 선택적 표적화, 병용적 통합을 통해 진화할 수 있을까?

부문

약물 유형 (디지털리스 배당체, 포스포디에스테라제 억제제, 심장 보호제, 교감 신경 모방제, 기타 약물 유형); 투여 경로 (경구, 비경구); 제형 (정제, 용액, 기타 제형); 유통 채널 (병원 약국, 소매 약국, 온라인 약국); 적용 (심장 수술, 심방 세동, 심부전, 폐 고혈압, 기타 응용 프로그램).

조사 대상 기업 예(총 34개사)

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Fresenius Kabi
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.05

Global Cardiotonic Agents Market to Reach US$3.0 Billion by 2030

The global market for Cardiotonic Agents estimated at US$1.0 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 19.4% over the analysis period 2024-2030. Digitalis Glycosides, one of the segments analyzed in the report, is expected to record a 21.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Phosphodiesterase Inhibitors segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.7 Million While China is Forecast to Grow at 26.5% CAGR

The Cardiotonic Agents market in the U.S. is estimated at US$284.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$720.8 Million by the year 2030 trailing a CAGR of 26.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Global Cardiotonic Agents Market - Key Trends & Drivers Summarized

Why Are Cardiotonic Agents Critical in Managing Acute and Chronic Heart Failure Across Diverse Care Settings?

Cardiotonic agents-primarily used to enhance myocardial contractility-remain a cornerstone in the pharmacologic management of heart failure, cardiogenic shock, and certain arrhythmias. These agents, including digitalis glycosides (e.g., digoxin), phosphodiesterase inhibitors (e.g., milrinone), and adrenergic agonists (e.g., dobutamine), provide vital hemodynamic support in cases of reduced ejection fraction or compromised cardiac output. Despite the emergence of novel heart failure therapies, cardiotonic drugs retain clinical importance due to their rapid onset of action, utility in acute decompensations, and established role in both intensive care and long-term heart failure treatment algorithms.

In acute settings such as ICU and emergency departments, cardiotonic agents are essential for stabilizing patients with life-threatening reductions in cardiac function. In chronic care, select agents like digoxin are used for rate control in atrial fibrillation and to reduce hospitalizations in heart failure with reduced ejection fraction (HFrEF), particularly when guideline-directed therapy is inadequate or contraindicated.

How Are New Drug Delivery Models and Risk Management Strategies Enhancing Use of Cardiotonic Therapies?

While concerns around toxicity and narrow therapeutic windows-particularly with older agents like digoxin-have historically limited broader use, advancements in dosing protocols, therapeutic drug monitoring (TDM), and personalized treatment regimens are improving safety and clinical outcomes. Intravenous formulations remain central to acute management, while oral options are used for maintenance therapy in chronic settings. Enhanced pharmacovigilance, digital monitoring tools, and patient-specific risk assessment models are helping clinicians optimize dosage, minimize adverse events, and extend safe usage across broader patient populations.

Clinical trials and observational studies are also driving renewed interest in combination strategies that pair cardiotonic agents with RAAS inhibitors, SGLT2 inhibitors, and beta blockers. In parallel, research into next-generation inotropes with improved myocardial efficiency and lower pro-arrhythmic risk profiles is progressing, aiming to redefine the role of contractility-enhancing agents in modern heart failure care.

Where Is Demand for Cardiotonic Agents Rising and Which Clinical Segments Are Leading Utilization?

North America and Europe remain key markets due to high heart failure prevalence, strong ICU infrastructure, and extensive use of acute care protocols. The U.S., in particular, continues to see widespread use of IV inotropes in hospital settings. Asia-Pacific is witnessing significant growth in demand, particularly in China, India, and Southeast Asia, where rising cardiovascular disease burden, aging populations, and expanding access to critical care are driving greater utilization.

Cardiotonic agents are used extensively in acute heart failure, post-operative cardiac support, and advanced heart failure where other pharmacologic measures are insufficient. High-use segments include cardiology units, intensive care wards, emergency departments, and cardiac surgery recovery programs. Additionally, outpatient heart failure clinics and geriatric care centers use lower-dose regimens for chronic maintenance in selected patient cohorts.

What Is Fueling the Global Growth of the Cardiotonic Agents Market?

The global cardiotonic agents market is expanding in response to the growing incidence of heart failure, increased demand for rapid-acting cardiovascular drugs, and the continued clinical reliance on inotropes and rate-control medications in acute decompensations. As cardiac care delivery becomes more protocol-driven and patient-centered, cardiotonic agents remain essential tools in stabilizing hemodynamics and bridging patients to longer-term therapies, interventions, or transplantation.

Pharmaceutical innovation in formulation refinement, dosing flexibility, and safety monitoring is helping maintain clinical confidence, while expanding global access to cardiac care is opening new markets in lower- and middle-income countries. As healthcare systems grapple with rising heart failure admissions and resource constraints, a critical question defines the future: Can cardiotonic therapies evolve through improved safety, selective targeting, and combinatory integration-while sustaining their frontline role in life-saving cardiac interventions across care settings?

SCOPE OF STUDY:

The report analyzes the Cardiotonic Agents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types); Administration Route (Oral, Parenteral); Dosage Form (Tablet, Solution, Other Dosage Forms); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Fresenius Kabi
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Cardiotonic Agents - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Hospitalization Rates for Heart Failure Reinforce Need for Cardiotonic Pharmacotherapy
    • Intravenous Inotropes Remain Standard in Acute Decompensated Heart Failure Management
    • Global Demand Stabilizes for Digoxin and Dobutamine Amid Entry of Next-Gen Cardiotonic Agents
    • Cardiotonic Therapies Integrated Into ICU Protocols for Short-Term Hemodynamic Support
    • Clinical Trials Evaluate Novel Cardiotonic Compounds With Reduced Pro-Arrhythmic Risk Profiles
    • Aging Populations and Comorbidity Prevalence Sustain Chronic Use of Oral Cardiotonic Medications
    • Hospital Formularies Prioritize Cost-Effective, Rapid-Onset Agents in Emergency Cardiac Care
    • Digital Drug Monitoring Tools Improve Safety in Titration and Therapeutic Drug Monitoring
    • Injectable Cardiotonic Agents Gain Inclusion in Global Critical Care Guidelines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cardiotonic Agents Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Digitalis Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cardioprotectants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Sympathomimetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Cardiac Surgical Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Heart Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Pulmonary Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: USA 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Canada 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Canada 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • JAPAN
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Japan 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Japan 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Japan Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Japan 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • CHINA
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 104: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: China 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: China Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: China 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 116: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: China Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: China 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • EUROPE
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 134: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • FRANCE
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 137: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 143: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: France Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: France 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: France Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: France 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 149: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: France Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: France 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • GERMANY
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 158: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Germany Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Germany 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Germany Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Germany 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 164: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Germany Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Germany 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 173: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Italy Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Italy 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Italy Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Italy 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 179: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Italy Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Italy 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 182: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 188: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UK Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UK 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 191: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UK Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UK 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 194: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UK Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UK 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 203: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Spain Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Spain 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Spain Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Spain 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 209: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Spain Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Spain 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 218: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Russia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Russia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Russia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Russia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 224: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Russia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Russia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 266: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Australia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Australia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Australia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Australia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 272: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Australia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Australia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • INDIA
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 275: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 281: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: India Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: India 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: India Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: India 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 287: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: India Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: India 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 296: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: South Korea Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: South Korea 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: South Korea Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: South Korea 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 302: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: South Korea Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: South Korea 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 335: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 344: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Argentina Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Argentina 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Argentina Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Argentina 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 350: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Argentina Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Argentina 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 359: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Brazil Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Brazil 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Brazil Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Brazil 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 365: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Brazil Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Brazil 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 374: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Mexico Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Mexico 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Mexico Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Mexico 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 380: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Mexico Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Mexico 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 409: Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 412: Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 413: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 415: Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 422: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Iran Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 424: Iran 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Iran Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 427: Iran 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 428: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Iran Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 430: Iran 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 437: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Israel Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 439: Israel 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Israel Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 442: Israel 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 443: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Israel Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 445: Israel 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 453: Saudi Arabia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 454: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 457: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 459: Saudi Arabia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 460: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 467: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 468: UAE Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 469: UAE 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 471: UAE Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 472: UAE 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 473: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 474: UAE Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 475: UAE 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Rest of Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 484: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 487: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Rest of Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 490: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
  • AFRICA
    • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
    • TABLE 497: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 498: Africa Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 499: Africa 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 501: Africa Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 502: Africa 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 503: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 504: Africa Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 505: Africa 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제